Clinical Trials
923 trialsNCT04401020 2026-05-29
First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL
Sanofi
Phase 1 Completed
NCT04130542 2026-05-19
Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy
Lyvgen Biopharma Holdings Limited
Phase 1 Completed
NCT04635995 2026-05-19
Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy
Lyvgen Biopharma Holdings Limited
Phase 1 Completed
NCT05076396 2026-05-11
PM14 Administered Intravenously to Patients With Advanced Solid Tumors
PharmaMar
Phase 1 Completed
NCT03872778 2026-04-30
NeoRay
Advanced Accelerator Applications
Phase 1/2 Completed
NCT05975073 2026-04-22
A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
Amgen
Phase 1/2 Completed
NCT06614140 2026-04-22
Personalized Neoantigen Cancer Vaccine for Patients With Solid Tumors
Seqker Biosciences, Inc.
Phase 1/2 Completed
NCT05377554 2026-04-13
Bevonescein for Intra-Operative Nerve Visualization in Head and Neck Surgery
Alume Biosciences, Inc.
Phase 3 Completed
NCT01968109 2026-04-06
An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT06238687 2026-04-06
A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors
Tasly Pharmaceutical Group Co., Ltd
Phase 1/2 Completed
NCT04050709 2026-04-01
QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers
ImmunityBio, Inc.
Phase 1 Completed
NCT05516914 2026-04-01
A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2 Completed
NCT03449381 2026-03-31
This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
Phase 1 Completed
NCT03833167 2026-03-10
KEYNOTE-630
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT06340815 2026-03-06
Varian ProBeam Proton Therapy System Clinical Trial (Shandong)
Varian, a Siemens Healthineers Company
Phase NA Completed
NCT01602380 2026-02-27
FALCON
AstraZeneca
Phase 3 Completed
NCT06056791 2026-02-27
CaRe
Inmune Bio, Inc.
Phase 1/2 Completed
NCT03976362 2026-02-25
KEYLYNK-008
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03964233 2026-02-18
A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)
Boehringer Ingelheim
Phase 1 Completed
NCT06676436 2026-02-18
REALNESS
AstraZeneca
Completed
NCT04260529 2026-01-29
CICILIA
Cytovation AS
Phase 1/2 Completed
NCT02952248 2026-01-27
A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT03697304 2026-01-27
Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours
Boehringer Ingelheim
Phase 2 Completed
NCT06163053 2026-01-14
A Study to Evaluate Satisfaction With Care in Patients With Cancer Receiving Immunotherapy Treatment at Home
Bristol-Myers Squibb
Completed
NCT04648254 2025-12-30
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor
Qurient Co., Ltd.
Phase 1 Completed
NCT03433898 2025-12-19
This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer
Boehringer Ingelheim
Phase EARLY_PHASE1 Completed
NCT02275910 2025-12-16
Phase 1 Study of E7090 in Subjects With Solid Tumor
Eisai Inc.
Phase 1 Completed
NCT05165433 2025-12-16
FORTIFY
Akamis Bio
Phase 1 Completed
NCT06347731 2025-12-15
Varian ProBeam360° Proton Therapy System China Clinical Trial (Wuhan)
Varian, a Siemens Healthineers Company
Phase NA Completed
NCT05383170 2025-11-28
Catalyst
Cytovation AS
Phase 1/2 Completed
NCT05586321 2025-11-24
Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors
Genmab
Phase 1 Completed
NCT03498521 2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2 Completed
NCT03363893 2025-11-12
Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies
Carrick Therapeutics Limited
Phase 1/2 Completed
NCT03486301 2025-11-12
EIK1001
Eikon Therapeutics
Phase 1 Completed
NCT03656718 2025-11-12
A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)
Bristol-Myers Squibb
Phase 1/2 Completed
NCT04196530 2025-11-12
EIK1001
Eikon Therapeutics
Phase 1 Completed
NCT04819373 2025-11-12
BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors
Eikon Therapeutics
Phase 2 Completed
NCT04840394 2025-11-12
Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Eikon Therapeutics
Phase 1 Completed
NCT03480646 2025-10-29
ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer
Constellation Pharmaceuticals
Phase 1/2 Completed
NCT05639751 2025-10-16
PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation
Prelude Therapeutics
Phase 1 Completed
NCT05514444 2025-10-09
MK-4464-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT03564691 2025-10-07
MK-4830-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT03972150 2025-10-06
A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer
Boehringer Ingelheim
Phase 1 Completed
NCT05407675 2025-10-03
A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT02674152 2025-10-01
Dose Finding Study of BI 836880 in Patients With Solid Tumors
Boehringer Ingelheim
Phase 1 Completed
NCT02689505 2025-10-01
Weekly BI 836880 in Patients With Advanced Solid Tumors
Boehringer Ingelheim
Phase 1 Completed
NCT06098651 2025-09-29
A Study of DCR-STAT3 in Adults With Solid Tumors
Novo Nordisk A/S
Phase 1 Completed
NCT04710043 2025-09-25
Dose Escalation Trial of BNT152+153 in Patients With Cancer
BioNTech SE
Phase 1 Completed
NCT05501821 2025-09-25
Study of KBA1412 in Participants With Advanced Solid Malignant Tumors
Kling Biotherapeutics B.V.
Phase 1 Completed
NCT05237206 2025-09-18
Study of SUPLEXA in Patients With Metastatic Solid Tumours and Haematologic Malignancies
Alloplex Biotherapeutics Inc
Phase 1 Completed